Vilazodone efficacy in subgroups of patients with major depressive disorder: a post-hoc analysis of four randomized, double-blind, placebo-controlled trials
| Autor: | Cheng-Tao Chang, Susan G. Kornstein, Carl Gommoll, John Edwards |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Adult
Male medicine.medical_specialty Adolescent Population Vilazodone Hydrochloride Patient Health Questionnaire Placebo law.invention 03 medical and health sciences chemistry.chemical_compound Young Adult 0302 clinical medicine Randomized controlled trial Double-Blind Method law Internal medicine Vilazodone Post-hoc analysis Medicine Humans Pharmacology (medical) Young adult education Aged Aged 80 and over Psychiatric Status Rating Scales education.field_of_study Depressive Disorder Major business.industry Middle Aged medicine.disease Antidepressive Agents 030227 psychiatry Psychiatry and Mental health Treatment Outcome chemistry Major depressive disorder Female business 030217 neurology & neurosurgery |
| Zdroj: | International clinical psychopharmacology. 33(4) |
| ISSN: | 1473-5857 |
| Popis: | The efficacy of antidepressants to treat major depressive disorder (MDD) varies by patient characteristics. This post-hoc analysis evaluated the effects of vilazodone across patient subgroups in adults with MDD. Data were pooled from four trials of vilazodone (NCT00285376, NCT00683592, NCT01473394, and NCT01473381). Mean change from baseline to week 8 in Montgomery-Asberg Depression Rating Scale (MADRS) total score, MADRS response (≥50% total score improvement), and MADRS remission (total score≤10) were analyzed in the pooled intent-to-treat population (vilazodone=1254, placebo=964) and in subgroups of patients categorized by sex, age, MDD duration, recurrent episodes, baseline MADRS total score, and current episode duration. MADRS total score improvement was significantly greater with vilazodone versus placebo in the intent-to-treat population and in all patient subgroups (P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|